SCHEDULE 13G/A: T. Rowe Price Associates Discloses 3.3% Passive Stake in Penumbra Inc.

T. Rowe Price Associates, Inc. has filed an amended Schedule 13G, reporting a passive beneficial ownership of 3.3% in Penumbra Inc.'s common stock as of December 31, 2024.

Summary

• T. Rowe Price Associates, Inc., an investment adviser based in Maryland, has filed an Amendment No. 2 to Schedule 13G.
• The filing discloses their beneficial ownership in Penumbra Inc. (CUSIP: 70975L107), a medical device company.
• As of December 31, 2024, T. Rowe Price Associates, Inc. beneficially owned an aggregate of 1,265,687 shares of Penumbra Inc. common stock.
• This represents 3.3% of Penumbra Inc.'s outstanding common stock.
• T. Rowe Price Associates, Inc. holds sole voting power over 1,243,568 shares and sole dispositive power over 1,265,687 shares.
• The filing indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Penumbra Inc.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of ownership, providing no positive or negative sentiment regarding the company's performance or outlook. It is a neutral regulatory filing.

Future Outlook

NA

Industry Context

This filing is a standard disclosure by a large institutional investor, T. Rowe Price Associates, Inc., indicating a passive stake in Penumbra Inc., a company operating in the medical device sector. Such disclosures are common and reflect portfolio management decisions rather than specific industry trends or competitive shifts.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's passive stake, which can be viewed as a vote of confidence in the company's long-term prospects by a major investment firm.

Key Dates

Keywords

Penumbra Inc, T. Rowe Price Associates, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Passive Investment, Medical Devices